The current price of MNPR is $71.42 — it has increased by 6.25% since the previous close. Data as of Nov 6, 2026.
MNPR is up 2.00% over the past week, down 14.75% over the past month and down 11.77% over the past year. The price is below its 200-day moving average of $77.22.
Analysts' average 12-month price target for MNPR is $126.00, which implies 76.42% upside from the current price. Individual estimates range from $105.00 to $145.00.
Of the 12 analysts covering Monopar Therapeutics Inc., 4 rate it a strong buy, 7 rate it a buy and 1 rates it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
Monopar Therapeutics Inc. has a market capitalization of $479.38M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
Monopar Therapeutics Inc. has not paid any dividends over the past year.
In the latest trading session MNPR moved between $67.47 and $72.25, a range of 6.69% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Monopar Therapeutics Inc. shows a sell rating today and a sell rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for Monopar Therapeutics Inc. is neutral. Technical ratings are indicators, not investment advice.
Over the past 52 weeks MNPR has traded between $50.07 and $124.82. The current price is 42.78% below its 52-week high.
Figures as of Nov 6, 2026. This information is provided for general purposes only and is not investment advice.